Molecular analysis of a recurrent glioblastoma treated with bevacizumab

Brain Tumor Pathology

Volumn 31, Issue 1, 2014, Pages 32-39

  Furuta, Takuya ^a   Nakada, Mitsutoshi ^a   Misaki, Kouichi ^a   Sato, Yasunori ^a   Hayashi, Yutaka ^a   Nakanuma, Yasuni ^a   Hamada, Jun Ichiro ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Bevacizumab; Glioblastoma; Invasion; Proliferation

Indexed keywords

BEVACIZUMAB; GELATINASE A; GLYCOGEN SYNTHASE KINASE 3BETA; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; TEMOZOLOMIDE; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; AUTOPSY; BRAIN HEMORRHAGE; CANCER RECURRENCE; CASE REPORT; CONTROLLED STUDY; DRUG WITHDRAWAL; DYSPHASIA; ENZYME PHOSPHORYLATION; FOLLOW UP; GLIOBLASTOMA; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEURONAVIGATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; DACARBAZINE; FATAL OUTCOME; FRONTAL LOBE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS C-AKT; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84895863876     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-013-0142-4     Document Type: Article

References (28)

1. Millauer B, Shawver LK, Plate KH et al (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576-579
2. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740
3. Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729 (Pubitemid 350086473)
4. Lai A, Tran A, Nghiemphu PL et al (2011) Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29:142-148
5. de Groot JF, Fuller G, Kumar AJ et al (2010) Radiographic and pathologic correlation in humans and mice. Neuro Oncol 12:233-242
6. Keunen O, Johansson M, Oudin A et al (2011) Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 108:3749-3754
7. Villano JL, Letarte N, Bressler LR (2012) Going past the data for temozolomide. Cancer Chemother Pharmacol 69:1113-1115
8. Chinot OL, de La Motte Rouge T, Moore N et al (2011) Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 28:334-340
9. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109 (Pubitemid 47103521)
10. Nakada M, Drake KL, Nakada S et al (2006) Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. Cancer Res 66:8492-8500 (Pubitemid 44449162)
11. Nakada M, Niska JA, Tran NL et al (2005) EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion. Am J Pathol 167:565-576 (Pubitemid 43026110)
12. Korkolopoulou P, Patsouris E, Kavantzas N et al (2002) Prognostic implications of microvessel morphometry in diffuse astrocytic neoplasms. Neuropathol Appl Neurobiol 28:57-66 (Pubitemid 34175513)
13. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6
14. Knizetova P, Ehrmann J, Hlobilkova A et al (2008) Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle 7:2553-2561
15. Steiner HH, Karcher S, Mueller MM et al (2004) Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels. J Neurooncol 66:129-138 (Pubitemid 38258367)
16. Lucio-Eterovic AK, Piao Y, de Groot JF (2009) Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 15:4589-4599
17. Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787
18. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891-899 (Pubitemid 39472955)
19. Du R, Petritsch C, Lu K et al (2008) Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro Oncol 10:254-264
20. Lu KV, Chang JP, Parachoniak CA et al (2012) VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22:21-35
21. Yoshimoto K, Ma X, Guan Y et al (2011) Expression of stem cell marker and receptor kinase genes in glioblastoma tissue quantified by real-time RT-PCR. Brain Tumor Pathol 28:291-296
22. Wick W, Weller M, Weiler M et al (2011) Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol 13:566-579
23. Nakada M, Kita D, Teng L et al (2013) Receptor tyrosine kinases: principles and functions in glioma invasion. Adv Exp Med Biol 986:143-170
24. Jones RB, Gordus A, Krall JA et al (2006) A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439:168-174 (Pubitemid 43083134)
25. Nazarenko I, Hede SM, He X et al (2012) PDGF and PDGF receptors in glioma. Upsala J Med Sci 117:99-112
26. Shibuya M (2006) Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 9:225-230
27. Stommel JM, Kimmelman AC, Ying H et al (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287-290 (Pubitemid 47574858)
28. Strick H, Deininger M, Streffer J et al (1999) BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry 67:763-768